{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"5.7","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Assessed by RECIST criteria. Summarized using summary statistics, such as the mean, median, counts and proportion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nbelinostat: Given IV","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"MEDIAN","populationDescription":"Eighteen patients with Epethelial Ovarian Cancer were analyzed","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Time to Disease Progression (Epithelial Ovarian Cancer Group)","type":"SECONDARY","unitOfMeasure":"months"}